Dual GLP-1 / GIP receptor agonist

Tirzepatide

Once-weekly dual-incretin agonist. Approved as Mounjaro (T2D) and Zepbound (weight management). Compounded tirzepatide is similarly dispensed by 503A/B pharmacies.

Trial outcome — SURMOUNT-1 (NEJM 2022)

20.9% body-weight reduction at 72 weeks at the 15 mg dose vs 3.1% placebo, in adults with overweight/obesity without diabetes

Dose schedule

2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg over 20+ weeks

Common side effects

  • • Nausea
  • • Diarrhea
  • • Constipation
  • • Decreased appetite
  • • Fatigue

Contraindications

  • • Personal/family history of medullary thyroid carcinoma
  • • MEN-2 syndrome
  • • Pregnancy
  • • Severe gastroparesis

FAQ

How does tirzepatide compare to semaglutide?
Head-to-head SURMOUNT studies suggest tirzepatide produces greater average weight reduction at higher doses. Individual response varies.
Why is tirzepatide more expensive?
It is a newer, more complex molecule. The compounded supply chain reflects that.
Can I switch from semaglutide?
Yes — your prescriber will manage the transition and dose adjustment.
Get matched

Want a real recommendation?

Five minutes. Free. No pressure.

Start my consultation